Aeon biopharma reports third quarter 2023 financial results

– announced topline results from phase 2 trial of abp-450 (prabotulinumtoxina) for the preventive treatment of episodic migraine that support advancing the program into a pivotal phase 3 study –

AEON Ratings Summary

AEON Quant Ranking